Editas Medicine (EDIT) Cash from Financing Activities (2015 - 2025)

Editas Medicine (EDIT) reported Cash from Financing Activities of $17.2 million for Q3 2025, up 131.64% on a QoQ basis from $7.4 million in Q2 2025.

Editas Medicine (EDIT) has 11 years of Cash from Financing Activities data on file, last reported at $17.2 million in Q3 2025.

  • Quarterly Cash from Financing Activities changed N/A year-over-year to $17.2 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $78.7 million (up 7551.46% YoY) and the FY2024 annual result came in at $56.0 million, down 52.54% from the prior year.
  • Cash from Financing Activities climbed to $17.2 million in Q3 2025 per EDIT's latest filing, from $7.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $261.5 million in Q1 2021 and bottomed at -$1.4 million in Q1 2025.
  • The 5-year median for Cash from Financing Activities is $838000.0 (2021), against an average of $30.0 million.
  • The widest annual swing landed in 2023, when Cash from Financing Activities soared 31923.16%; it then sank 848.44% in 2025.
  • Tracing EDIT's Cash from Financing Activities over 5 years: stood at $1.1 million in 2021, then plunged by 41.44% to $619000.0 in 2022, then declined by 16.96% to $514000.0 in 2023, then surged by 10700.19% to $55.5 million in 2024, then tumbled by 69.07% to $17.2 million in 2025.
  • Per Business Quant, the three latest EDIT Cash from Financing Activities figures stand at $17.2 million (Q3 2025), $7.4 million (Q2 2025), and -$1.4 million (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 7.00 Mn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -600,000.00
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - 53,000.00
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -538.80 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -802.20 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 15.71 Mn
10 Editas Medicine 338.62 Mn 338.62 Mn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2025 17.17 Mn
Sep 30, 2025 17.17 Mn
Jun 30, 2025 7.41 Mn
Jun 30, 2025 7.41 Mn
Mar 31, 2025 -1.44 Mn
Mar 31, 2025 -1.44 Mn
Dec 31, 2024 55.51 Mn
Dec 31, 2024 55.51 Mn
Jun 30, 2024 322,000.00
Jun 30, 2024 322,000.00
Mar 31, 2024 192,000.00
Mar 31, 2024 192,000.00
Dec 31, 2023 514,000.00
Dec 31, 2023 514,000.00
Jun 30, 2023 117.53 Mn
Jun 30, 2023 117.53 Mn
Dec 31, 2022 619,000.00
Dec 31, 2022 619,000.00
Sep 30, 2022 80,000.00
Sep 30, 2022 80,000.00
Jun 30, 2022 367,000.00
Jun 30, 2022 367,000.00
Mar 31, 2022 218,000.00
Mar 31, 2022 218,000.00
Dec 31, 2021 1.06 Mn
Dec 31, 2021 1.06 Mn
Sep 30, 2021 2.50 Mn
Sep 30, 2021 2.50 Mn
Jun 30, 2021 17.08 Mn
Jun 30, 2021 17.08 Mn
Mar 31, 2021 261.47 Mn
Mar 31, 2021 261.47 Mn
Dec 31, 2020 9.10 Mn
Dec 31, 2020 9.10 Mn
Sep 30, 2020 822,000.00
Sep 30, 2020 822,000.00
Jun 30, 2020 211.15 Mn
Jun 30, 2020 211.15 Mn
Mar 31, 2020 3.05 Mn
Mar 31, 2020 3.05 Mn
Dec 31, 2019 84.57 Mn
Dec 31, 2019 84.57 Mn
Sep 30, 2019 43.35 Mn
Sep 30, 2019 43.35 Mn
Jun 30, 2019 2.37 Mn
Jun 30, 2019 2.37 Mn
Mar 31, 2019 1.53 Mn
Mar 31, 2019 1.53 Mn
Dec 31, 2018 30.35 Mn
Dec 31, 2018 30.35 Mn
Sep 30, 2018 1.24 Mn
Sep 30, 2018 1.24 Mn
Jun 30, 2018 2.67 Mn
Jun 30, 2018 2.67 Mn
Mar 31, 2018 52.68 Mn
Mar 31, 2018 52.68 Mn
Sep 30, 2017 96.06 Mn
Sep 30, 2017 96.06 Mn
Jun 30, 2017 96.79 Mn
Jun 30, 2017 96.79 Mn
Mar 31, 2017 97.09 Mn
Mar 31, 2017 97.09 Mn
Dec 31, 2016 -538,000.00
Dec 31, 2016 -538,000.00
Sep 30, 2016 -22,000.00
Sep 30, 2016 -22,000.00
Jun 30, 2016 -494,000.00
Jun 30, 2016 -494,000.00
Mar 31, 2016 98.22 Mn
Mar 31, 2016 98.22 Mn
Dec 31, 2015 -3.75 Mn
Dec 31, 2015 -3.75 Mn
Sep 30, 2015 120.39 Mn
Sep 30, 2015 120.39 Mn
Jun 30, 2015 21.96 Mn
Jun 30, 2015 21.96 Mn
Mar 31, 2015 791,000.00
Mar 31, 2015 791,000.00